[Efficacy and safety of lycopene in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms].

Objective: To investigate the efficacy and safety of lycopene in the treatment of BPH with lower urinary tract symptoms (LUTS).

Methods: Totally, 127 BPH patients with LUTS were treated with oral lycopene tablets at 500 mg bid in the Department of Andrology of Jinling Hospital from January 2018 to January 2019. At 8 and 16 weeks of medication, we compared the IPSS, quality of life (QOL) score, prostate volume, PSA level, maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR) and the incidence of adverse reactions before and after treatment.

Results: A total of 120 patients completed the treatment. Compared with the baseline, significant improvement was observed after 8 weeks of medication in the IPSS (［18.42 ± 4.59］ vs ［14.13 ± 4.51］, P < 0.01) and QOL score (［4.34 ± 1.37］ vs ［3.14 ± 1.25］, P < 0.01), and even more significant at 16 weeks in the IPSS (［18.42 ± 4.59］ vs ［10.29 ± 3.61］, P< 0.01), QOL score (［4.34 ± 1.37］ vs ［2.17 ± 1.35］, P < 0.01), PSA (［3.87 ± 3.14］ vs ［2.90 ± 3.07］ μg/L, P < 0.01), Qmax (［10.62 ± 2.08］ vs ［14.15 ± 3.66］ ml/s, P < 0.01) and PVR (［35.88 ± 15.33］ vs ［18.36 ± 13.09］ ml, P < 0.01), but there was no statistically significant difference in the prostate volume before and after treatment (［39.85 ± 10.22］ vs ［38.16 ± 10.12］ ml, P > 0.05), and no adverse reactions in any of the patients.

Conclusions: Lycopene has a good therapeutic effect on BPH with LUTS, which can significantly improve the patients' quality of life without causing adverse reactions.